

**Administration**

**PATIENT GROUP DIRECTION (PGD) FOR**

**PROXYMETACAINE 0.5% EYE DROPS**

**YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT**

<b>Clinical Condition</b>	
<b>Indication</b>	To be used as a topical ocular local anaesthetic
<b>Inclusion criteria</b>	Patients presenting in MIU with conditions requiring examination, removal of foreign bodies or irrigation of the eye
<b>Exclusion criteria</b> If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Known hypersensitivity to any of the ingredients of the drops Premature babies Traumatised eye and penetrating injuries Red (inflamed) eye without history of trauma
<b>Cautions - Seek further advice from doctor before proceeding and document advice</b>	Not to be used with contact lenses in situ When using with fluorescein, instil after the eye has been anaesthetised. Safety for use in pregnancy and lactation has not been established, therefore, use only when considered essential This product should be used cautiously and sparingly in patients with known allergies, cardiac disease or hyperthyroidism because of the increased risk of sensitivity reactions.
<b>Further information</b>	The drops may be washed away with sterile isotonic sodium chloride 0.9% solution (normal saline) A period of one minute must be left before administration of any other eye drops Do not use if the solution is more than pale yellow in colour. Discard after single use. Store unrefrigerated at below 25°C
<b>Action if patient declines or is excluded</b>	Refer to doctor / A&E / ophthalmologist as appropriate and document
<b>Drug Details</b>	
<b>Name, form &amp; strength of medicine</b>	Proxymetacaine hydrochloride 0.5% single use sterile eye drops (minims)
<b>Legal status</b>	Prescription Only Medicine (POM)
<b>Route/Method</b>	Into the affected eye or eyes Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following instillation of the drops. (This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially useful in children).
<b>Dosage</b>	Instil one or two drops
<b>Frequency</b>	Once only
<b>Quantity to administer</b>	See above

**Administration**  
**PATIENT GROUP DIRECTION (PGD) FOR**

**PROXYMETACAINE 0.5% EYE DROPS**




<b>Side effects</b>	May cause transient blurring of vision on instillation
<b>Advice to patient/carer</b>	Protection of the eye from rubbing, irritating chemicals and foreign bodies during the period of anaesthesia is very important. Patients should be advised to avoid touching the eye until the anaesthesia has worn off. Warn patients not to drive or operate hazardous machinery unless vision is clear (blurring of vision on instillation). Anaesthesia lasts for approximately 30 minutes. Do not wear contact lenses for 24 hours after the anaesthesia
<b>Follow up</b>	Patient should be followed up by GP at 24 to 48 hours

<b>Staff Characteristics</b>	
<b>Professional qualifications</b>	Nurses on the NMC Register
<b>Specialist competencies or qualifications</b>	A registered nurse, after discussion and agreement with the MIU service/departmental lead. Has undertaken training to carry out clinical assessment of minor injuries to eyes leading to diagnosis that requires treatment according to the indications listed in this PGD Has undertaken appropriate training for working under PGDs for the supply and administration of medicines Has undertaken training in the management of anaphylaxis
<b>Continuing education &amp; training</b>	The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development
<b>Referral Arrangements and Audit Trail</b>	
<b>Records/audit trail</b>	Patient's name, address, date of birth. Contact details of GP (if registered). Diagnosis. Advice given to patient (including side effects). Signature/name of staff who administered the medication. Details of any adverse drug reaction and actions taken including documentation in the patient's medical record Referral arrangements (including self-care) Record the use of the PGD in the departmental log.
<b>References/Resources and comments</b>	Summary of Product Characteristics British National Formulary

**Administration**

**PATIENT GROUP DIRECTION (PGD) FOR**

**PROXYMETACAINE 0.5% EYE DROPS**

Clinical Authorisation	
<b>Lead Doctor</b>	Dr John Devapriam, Medical Director  Signature:  Date: 14/6/18
<b>Lead Pharmacist</b>	Dr Alex Johnson, Prescribing Support Pharmacist  Signature:  Date: 26.6.18
Organisational Authorisation	
<b>On behalf of Worcestershire Health and Care NHS Trust</b>	Michelle Clarke, Director of Nursing and Quality  Signature:  Date: 18/6/18
Patient Group Direction Peer Reviewed by	
Senior MIU Nurses	

